CL2020002796A1 - Derivados de gip y usos de estos - Google Patents
Derivados de gip y usos de estosInfo
- Publication number
- CL2020002796A1 CL2020002796A1 CL2020002796A CL2020002796A CL2020002796A1 CL 2020002796 A1 CL2020002796 A1 CL 2020002796A1 CL 2020002796 A CL2020002796 A CL 2020002796A CL 2020002796 A CL2020002796 A CL 2020002796A CL 2020002796 A1 CL2020002796 A1 CL 2020002796A1
- Authority
- CL
- Chile
- Prior art keywords
- gip
- relates
- peptides
- derivatives
- nash
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a péptidos novedosos que son derivados de análogos del polipéptido insulinotrópico dependiente de la glucosa (GIP) que tienen una estabilidad física mejorada en solución y un perfil de acción prolongado. Más en particular, la invención se refiere a dichos péptidos que son agonistas del receptor de GIP y a su uso en el control del peso o para el tratamiento de enfermedades tales como la obesidad, la diabetes o la esteatohepatitis no alcohólica (NASH).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862666916P | 2018-05-04 | 2018-05-04 | |
EP18172827 | 2018-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020002796A1 true CL2020002796A1 (es) | 2021-02-19 |
Family
ID=66440040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020002796A CL2020002796A1 (es) | 2018-05-04 | 2020-10-28 | Derivados de gip y usos de estos |
Country Status (20)
Country | Link |
---|---|
US (2) | US10604555B2 (es) |
EP (1) | EP3788063B1 (es) |
JP (2) | JP6818940B2 (es) |
KR (1) | KR102379958B1 (es) |
CN (1) | CN112074531A (es) |
AU (1) | AU2019263674B2 (es) |
BR (1) | BR112020022027A2 (es) |
CA (1) | CA3097939A1 (es) |
CL (1) | CL2020002796A1 (es) |
CO (1) | CO2020014180A2 (es) |
ES (1) | ES2961384T3 (es) |
IL (1) | IL278171A (es) |
MA (1) | MA52483A (es) |
MX (1) | MX2020011427A (es) |
PE (1) | PE20210473A1 (es) |
PH (1) | PH12020551742A1 (es) |
RU (1) | RU2020136305A (es) |
SG (1) | SG11202010297UA (es) |
TW (1) | TWI707865B (es) |
WO (1) | WO2019211451A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
CN109923114B (zh) | 2016-09-09 | 2022-11-01 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途 |
LT3755703T (lt) | 2018-02-20 | 2022-10-10 | Incyte Corporation | N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
ES2961384T3 (es) * | 2018-05-04 | 2024-03-11 | Novo Nordisk As | Derivados de GIP y usos de los mismos |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
PE20221419A1 (es) | 2019-08-06 | 2022-09-20 | Incyte Corp | Formas solidas de un inhibidor de hpk1 |
KR20220145888A (ko) | 2020-03-06 | 2022-10-31 | 사노피 | 선택적 gip 수용체 작용제로서의 펩티드 |
JP2023520769A (ja) | 2020-03-31 | 2023-05-19 | アンタロス メディカル アクティエボラーグ | イメージング及び治療目的のキレート部分を含む選択的gip受容体アゴニスト |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
CA3184717A1 (en) | 2020-07-22 | 2022-01-27 | Patrick J. KNERR | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
EP4240749A1 (en) * | 2020-11-09 | 2023-09-13 | Embark Biotech ApS | Compounds and their use in treatment of tachykinin receptor mediated disorders |
CN117545471A (zh) | 2021-06-23 | 2024-02-09 | 佩特通公司 | 包含塞马格鲁肽或其药学上可接受的盐的缓释制剂组合物 |
AU2022339059A1 (en) | 2021-09-06 | 2024-05-02 | Sanofi | New peptides as potent and selective gip receptor agonists |
WO2023118263A1 (en) * | 2021-12-21 | 2023-06-29 | Embark Biotech Aps | Agonists for treatment of eating disorder |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
WO2023151594A1 (en) * | 2022-02-11 | 2023-08-17 | Hangzhou Sciwind Biosciences Co., Ltd. | A composition comprising gip receptor agonists and glp-1 receptor agonists and use thereof |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60012721T4 (de) | 1999-03-29 | 2010-09-09 | Uutech Ltd., Coleraine | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
GB0404124D0 (en) * | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
KR20110040760A (ko) | 2008-06-17 | 2011-04-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 질환 및 비만 치료용 gip-기초된 혼합형 항진제 |
EP2320923B1 (en) | 2008-08-07 | 2014-12-24 | Ipsen Pharma S.A.S. | Truncated analogues of glucose-dependent insulinotropic polypeptide |
MX2011001031A (es) | 2008-08-07 | 2011-04-26 | Ipsen Pharma Sas | Analogos de polipeptidos insulinotropicos dependientes de glucosa. |
EP2323678B1 (en) | 2008-08-07 | 2016-03-23 | Ipsen Pharma S.A.S. | Glucose-dependent insulinotropic polypeptide analogues |
AU2009280021B2 (en) | 2008-08-07 | 2012-10-04 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
KR101817607B1 (ko) | 2009-12-16 | 2018-01-11 | 노보 노르디스크 에이/에스 | 이중 아실화된 glp―1 유도체 |
BR112012018585A2 (pt) | 2010-01-27 | 2017-01-10 | Univ Indiana Res & Tech Corp | conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade |
CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
BR112012028707A2 (pt) | 2010-05-13 | 2019-09-24 | Univ Indiana Res & Tech Corp | composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo. |
US9249181B2 (en) * | 2010-09-13 | 2016-02-02 | Amylin Pharmaceuticals, Llc | C-terminal amidation of polypeptides |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
AU2011348202A1 (en) | 2010-12-22 | 2013-07-04 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with GIP and GLP-1 receptor-active glucagon-based peptides |
KR102002783B1 (ko) | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
US20130090285A1 (en) | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
TR201815338T4 (tr) | 2012-05-03 | 2018-11-21 | Zealand Pharma As | Gıp-glp-1 dual agonist bileşikleri ve yöntemler. |
CN104583233B (zh) | 2012-06-21 | 2018-10-23 | 印第安纳大学研究及科技有限公司 | 表现出gip受体活性的胰高血糖素的类似物 |
RU2678134C2 (ru) | 2013-03-14 | 2019-01-23 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Конъюгаты инсулин-инкретин |
MY174727A (en) | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
SI3004155T1 (sl) | 2013-05-28 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Peptidna spojina |
CN105451776B (zh) | 2013-08-15 | 2020-04-17 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
US10093713B2 (en) | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
JP2017503474A (ja) | 2013-11-06 | 2017-02-02 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン−glp−1−gipトリプルアゴニスト化合物 |
US10570184B2 (en) * | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
EP3189072B1 (en) | 2014-09-05 | 2018-07-18 | University of Copenhagen | Gip peptide analogues |
BR112017008659A2 (pt) | 2014-10-29 | 2018-01-30 | Zealand Pharma As | ?métodos e compostos de agonista de gip? |
EP3226906B1 (en) * | 2014-11-27 | 2019-06-12 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
EP3262041A4 (en) | 2015-02-27 | 2018-08-01 | Lycera Corporation | Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease |
WO2016205488A1 (en) | 2015-06-17 | 2016-12-22 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
US20190175744A1 (en) | 2016-03-18 | 2019-06-13 | Merck Sharp & Dohme Corp. | Insulin-incretin conjugates |
WO2017210168A1 (en) | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Aqueously soluble and chemically stable depsi glucagon agonists |
JP2020521784A (ja) * | 2017-05-31 | 2020-07-27 | ユニバーシティ オブ コペンハーゲン | 長時間作用性gipペプチド類似体 |
ES2961384T3 (es) * | 2018-05-04 | 2024-03-11 | Novo Nordisk As | Derivados de GIP y usos de los mismos |
-
2019
- 2019-05-03 ES ES19722582T patent/ES2961384T3/es active Active
- 2019-05-03 PE PE2020001751A patent/PE20210473A1/es unknown
- 2019-05-03 MA MA052483A patent/MA52483A/fr unknown
- 2019-05-03 BR BR112020022027-2A patent/BR112020022027A2/pt not_active Application Discontinuation
- 2019-05-03 CN CN201980029824.2A patent/CN112074531A/zh active Pending
- 2019-05-03 EP EP19722582.4A patent/EP3788063B1/en active Active
- 2019-05-03 MX MX2020011427A patent/MX2020011427A/es unknown
- 2019-05-03 CA CA3097939A patent/CA3097939A1/en not_active Withdrawn
- 2019-05-03 WO PCT/EP2019/061413 patent/WO2019211451A1/en active Application Filing
- 2019-05-03 JP JP2020512588A patent/JP6818940B2/ja active Active
- 2019-05-03 US US16/403,241 patent/US10604555B2/en active Active
- 2019-05-03 AU AU2019263674A patent/AU2019263674B2/en active Active
- 2019-05-03 TW TW108115352A patent/TWI707865B/zh active
- 2019-05-03 KR KR1020207034171A patent/KR102379958B1/ko active IP Right Grant
- 2019-05-03 US US17/052,702 patent/US11633459B2/en active Active
- 2019-05-03 SG SG11202010297UA patent/SG11202010297UA/en unknown
- 2019-05-03 RU RU2020136305A patent/RU2020136305A/ru unknown
-
2020
- 2020-04-09 JP JP2020070421A patent/JP2020125311A/ja not_active Withdrawn
- 2020-10-20 PH PH12020551742A patent/PH12020551742A1/en unknown
- 2020-10-20 IL IL278171A patent/IL278171A/en unknown
- 2020-10-28 CL CL2020002796A patent/CL2020002796A1/es unknown
- 2020-11-12 CO CONC2020/0014180A patent/CO2020014180A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20210473A1 (es) | 2021-03-08 |
JP6818940B2 (ja) | 2021-01-27 |
EP3788063A1 (en) | 2021-03-10 |
RU2020136305A (ru) | 2022-05-05 |
CN112074531A (zh) | 2020-12-11 |
JP2020528925A (ja) | 2020-10-01 |
US10604555B2 (en) | 2020-03-31 |
MA52483A (fr) | 2021-03-10 |
EP3788063C0 (en) | 2023-08-09 |
IL278171A (en) | 2020-11-30 |
CO2020014180A2 (es) | 2021-01-29 |
KR102379958B1 (ko) | 2022-04-01 |
CA3097939A1 (en) | 2019-11-07 |
SG11202010297UA (en) | 2020-11-27 |
BR112020022027A2 (pt) | 2021-02-02 |
AU2019263674B2 (en) | 2023-03-02 |
US20220000982A1 (en) | 2022-01-06 |
TW202003550A (zh) | 2020-01-16 |
KR20210005700A (ko) | 2021-01-14 |
TWI707865B (zh) | 2020-10-21 |
EP3788063B1 (en) | 2023-08-09 |
US11633459B2 (en) | 2023-04-25 |
US20190367578A1 (en) | 2019-12-05 |
AU2019263674A1 (en) | 2020-11-26 |
WO2019211451A1 (en) | 2019-11-07 |
ES2961384T3 (es) | 2024-03-11 |
MX2020011427A (es) | 2020-12-07 |
PH12020551742A1 (en) | 2021-06-28 |
JP2020125311A (ja) | 2020-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002796A1 (es) | Derivados de gip y usos de estos | |
CY1122539T1 (el) | Αναλογα γλυκαγονης | |
CY1121462T1 (el) | Ακυλιωμενα αναλογα γλυκαγονης | |
CO7400885A2 (es) | Análogos de glucagón | |
PE20210162A1 (es) | Analogos de incretina y sus usos | |
MX2023010869A (es) | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. | |
CL2014003421A1 (es) | Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad. | |
ECSP19046893A (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip | |
ECSP12012357A (es) | Análogos del glucagón | |
MX2016016868A (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagon. | |
CL2019001683A1 (es) | Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas. | |
ECSP12011593A (es) | Análogos de glucagón acilados | |
UY33462A (es) | Analogos de glucagon | |
PE20170087A1 (es) | Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon | |
MX2017012864A (es) | Analogo acilado del glucagon. | |
CL2020000812A1 (es) | Semaglutida en la terapia médica. | |
CO2020002500A2 (es) | Análogos de insulina acilados novedosos y usos de estos | |
AR115077A1 (es) | Derivados de gip y sus usos | |
ECSP15009978A (es) | Análogos de glucagón | |
CO6382136A2 (es) | Análogos de glucagón | |
EA201791103A1 (ru) | Терапевтический гомодимер и его применения |